[go: up one dir, main page]

PL4199946T3 - Agoniści receptora crf2 i ich zastosowanie w terapii - Google Patents

Agoniści receptora crf2 i ich zastosowanie w terapii

Info

Publication number
PL4199946T3
PL4199946T3 PL21777954.5T PL21777954T PL4199946T3 PL 4199946 T3 PL4199946 T3 PL 4199946T3 PL 21777954 T PL21777954 T PL 21777954T PL 4199946 T3 PL4199946 T3 PL 4199946T3
Authority
PL
Poland
Prior art keywords
therapy
application
receptor agonists
crf2 receptor
crf2
Prior art date
Application number
PL21777954.5T
Other languages
English (en)
Inventor
Stephane Illiano
Laurence LUCATS
Laetitia LEDEIN
Philippe Beauverger
Philip Janiak
Marie-Laure Ozoux
Nis Halland
Ziyu Li
Ralf Elvert
Andreas Evers
Elisabetta Bianchi
Alessia Santoprete
Daniela ROVERSI
Martina TRIPEPI
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of PL4199946T3 publication Critical patent/PL4199946T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57509Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2228Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL21777954.5T 2020-08-19 2021-08-18 Agoniści receptora crf2 i ich zastosowanie w terapii PL4199946T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20315387 2020-08-19
PCT/EP2021/072923 WO2022038179A1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
PL4199946T3 true PL4199946T3 (pl) 2024-08-19

Family

ID=72615799

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21777954.5T PL4199946T3 (pl) 2020-08-19 2021-08-18 Agoniści receptora crf2 i ich zastosowanie w terapii

Country Status (16)

Country Link
US (1) US20250243255A1 (pl)
EP (2) EP4435001A3 (pl)
JP (1) JP2023541798A (pl)
KR (1) KR20230051583A (pl)
CN (1) CN116472053A (pl)
AU (1) AU2021328673A1 (pl)
CA (1) CA3192032A1 (pl)
ES (1) ES2988026T3 (pl)
HR (1) HRP20240906T1 (pl)
HU (1) HUE066991T2 (pl)
IL (1) IL300464A (pl)
IS (1) IS3063B (pl)
MX (1) MX2023002087A (pl)
PL (1) PL4199946T3 (pl)
WO (1) WO2022038179A1 (pl)
ZA (1) ZA202301784B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
EP4234574A1 (en) * 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
WO2025104264A1 (en) 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
WO2025222010A1 (en) * 2024-04-19 2025-10-23 Neurocrine Biosciences, Inc. Corticotropin releasing factor receptor 2 (crfr2) agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Also Published As

Publication number Publication date
EP4435001A2 (en) 2024-09-25
EP4435001A3 (en) 2024-10-09
HRP20240906T1 (hr) 2024-10-11
IL300464A (en) 2023-04-01
JP2023541798A (ja) 2023-10-04
CA3192032A1 (en) 2022-02-24
ES2988026T3 (es) 2024-11-19
HUE066991T2 (hu) 2024-09-28
ZA202301784B (en) 2024-01-31
MX2023002087A (es) 2023-03-23
CN116472053A (zh) 2023-07-21
EP4199946B1 (en) 2024-06-05
WO2022038179A1 (en) 2022-02-24
KR20230051583A (ko) 2023-04-18
EP4199946C0 (en) 2024-06-05
IS3063B (is) 2025-06-15
AU2021328673A1 (en) 2023-03-30
US20250243255A1 (en) 2025-07-31
EP4199946A1 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
PL4199946T3 (pl) Agoniści receptora crf2 i ich zastosowanie w terapii
SI3806955T1 (sl) Agonisti receptorja glp-1 in njihova uporaba
EP4247801A4 (en) 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
IL282487A (en) Tyk2 inhibitors and uses thereof
IL284210A (en) Compounds that participate in cooperative binding and uses thereof
SI3658557T1 (sl) Zaviralci TYK2 in njihova uporaba
EP3858856A4 (en) ANTI-B7-H3 MONOCLONAL ANTIBODY AND ITS USE IN CELLULAR THERAPY
DK3707159T5 (da) Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf
IL286248B2 (en) Tyk2 inhibitors and uses thereof
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
IL308755A (en) T cell receptors targeting ras mutations and uses thereof
MX390159B (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada.
EP4212524A4 (en) Cd73 inhibitor and application thereof in medicine
DK3423496T3 (da) Ikke-antagonistiske antistoffer rettet mod alfakæden i IL7-receptorens ekstracellulære domæne og anvendelse deraf i kræftbehandling
PL3768284T3 (pl) Kompozycje z fageliny entrecoccus do zastosowania w terapii
IL312330A (en) Tyk2 degraders and uses thereof
IL311331A (en) Pharmaceutical composition and use thereof
EP4444324A4 (en) MODIFIED T CELL RECEPTORS AND THEIR USES
IL311837A (en) Compositions targeting bcma and methods of use thereof
IS050770A (is) CRF2 viðtakaverkar og notkun þeirra í meðferð
IL282926A (en) T cell receptors specific for mesothelin and their use in immunotherapy
IL312874A (en) Pharmaceutical composition and use thereof
EP4326771A4 (en) CHIMERIC CYTOKINE RECEPTORS AND THEIR USES IN CELLULAR THERAPIES
DK4428503T3 (da) Distributionsforsyningsindretning og kombineret vejeindretning med samme
EP4396214A4 (en) DLL3 Targeting Antigen Receptors and Their Uses